peficitinib

a Janus kinase inhibitor; structure in first source

Also Known As:

4-((5-hydroxy-2-adamantyl)amino)-1H-pyrrolo(2,3-b)pyridine-5-carboxamide; 4-((trans-5-hydroxyadamantan-2-yl)amino)-1H-pyrrolo(2,3-b)pyridine-5-carboxamide; ASP015K; 4-(((1R,2s,3S,5s,7s)-5-Hydroxyadamantan-2-yl)amino)-1H-pyrrolo(2,3-b)pyridine-5-carboxamide

Networked: 61 relevant articles (13 outcomes, 26 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kaneko, Yuichiro: 16 articles (07/2022 - 06/2016)
2.	Tanaka, Yoshiya: 14 articles (07/2022 - 06/2016)
3.	Izutsu, Hiroyuki: 12 articles (07/2022 - 10/2019)
4.	Takeuchi, Tsutomu: 11 articles (07/2022 - 06/2016)
5.	Rokuda, Mitsuhiro: 9 articles (07/2022 - 10/2019)
6.	Kato, Daisuke: 6 articles (07/2022 - 01/2021)
7.	Fukuda, Musashi: 5 articles (07/2022 - 01/2021)
8.	Kawakami, Atsushi: 5 articles (03/2021 - 10/2019)
9.	Tanaka, Sakae: 5 articles (03/2021 - 10/2019)
10.	Ushijima, Satoshi: 5 articles (03/2021 - 10/2019)

Related Diseases

1.	Rheumatoid Arthritis 06/15/2023 - "Post hoc analysis of patients with rheumatoid arthritis (RA) under clinical remission in two Japanese phase 3 trials of peficitinib treatment (RAJ3, RAJ4)." 01/03/2023 - "To determine the efficacy of peficitinib in reducing joint damage and predictive factors affecting treatment response in Japanese patients with rheumatoid arthritis. " 07/01/2022 - "Discussion: In the two cases presented here, rheumatoid arthritis was almost in remission and there were no adverse events, although the patients were switched to peficitinib after secondary failure of the biologic agents. " 07/01/2022 - "This was a post hoc analysis of pooled data from one Phase 2b study and two Phase 3 studies and final data from a long-term extension study of peficitinib in Asian rheumatoid arthritis patients. " 06/01/2020 - "Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials."
2.	Arthritis (Polyarthritis) 01/01/2022 - "Administration of peficitinib for established CIA ameliorated arthritis and improved BMD in the femoral metaphysis, but not in the femoral diaphysis. " 01/01/2017 - "Furthermore, peficitinib dose-dependently suppressed bone destruction and paw swelling in an adjuvant-induced arthritis model in rats via prophylactic or therapeutic oral dosing regimens. " 02/15/2023 - "In conclusion, both tofacitinib and peficitinib potently improved arthritis and associated symptoms in adjuvant-induced arthritis rats; moreover, owing to possible differences in the mechanism of action of the two drugs, peficitinib may have exerted its effects through JAK inhibition and additional unique off-target properties." 02/15/2023 - "Equivalent Cmax and AUC0-12h values were observed with peficitinib 10 mg/kg and tofacitinib 3 mg/kg, suggesting that the two drugs may demonstrate comparable efficacy on arthritis-associated symptoms at comparable plasma concentration levels. " 02/15/2023 - "Comparison of the effects of peficitinib and tofacitinib in the adjuvant-induced arthritis rat model."
3.	Dermatomyositis (Dermatopolymyositis) 01/01/2022 - "This is the first report showing that peficitinib is effective for anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis and it may be a potential treatment option." 01/01/2022 - "Successful peficitinib addition on anti-MDA5 antibody-positive dermatomyositis refractory to triple therapy and glucocorticoid reduction." 01/01/2022 - "Here, we describe a case of a 50-year-old woman with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis who became refractory to triple therapy and prednisolone reduction, and achieved remission with the addition of peficitinib, a JAK inhibitor. " 12/01/2020 - "We also discuss the efficacy of the first- and second-generation JAK inhibitors (tofacitinib, baricitinib, ruxolitinib, peficitinib, filgotinib, upadacitinib, solcitinib, itacitinib, decernotinib, R333, and pf-06651600) for CTDs including RA, systemic lupus erythematosus, dermatomyositis, systemic sclerosis, Sjögren's syndrome, and vasculitis, based on laboratory and clinical research findings. "
4.	Melanoma (Melanoma, Malignant) 01/01/2022 - "This is the first report showing that peficitinib is effective for anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis and it may be a potential treatment option." 05/01/2021 - "Respective peficitinib and placebo incidence rates (95% confidence interval) per 100 PY were 2.9 (1.9, 4.6) and 0.0 for serious infections, 5.7 (4.2, 7.9) and 2.3 (0.6, 9.4) for herpes zoster-related disease, and 0.6 (0.2, 1.6) and 1.2 (0.2, 8.3) for malignancies (excluding non-melanoma skin cancer) (Phase 3 studies), and 0.1 (0.0, 0.3) for venous thromboembolism in all peficitinib-treated patients (Phase 2/3 studies). " 01/01/2022 - "Here, we describe a case of a 50-year-old woman with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis who became refractory to triple therapy and prednisolone reduction, and achieved remission with the addition of peficitinib, a JAK inhibitor. "
5.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 04/01/2020 - "filgotinib and peficitinib, are being and were investigated in various studies on indications, such as atopic dermatitis, ankylosing spondylitis and systemic lupus erythematosus. " 12/01/2020 - "We also discuss the efficacy of the first- and second-generation JAK inhibitors (tofacitinib, baricitinib, ruxolitinib, peficitinib, filgotinib, upadacitinib, solcitinib, itacitinib, decernotinib, R333, and pf-06651600) for CTDs including RA, systemic lupus erythematosus, dermatomyositis, systemic sclerosis, Sjögren's syndrome, and vasculitis, based on laboratory and clinical research findings. "

Related Drugs and Biologics

1.	Janus Kinase Inhibitors
2.	peficitinib
3.	tofacitinib
4.	baricitinib
5.	GLPG0634
6.	upadacitinib
7.	Janus Kinases
8.	Antirheumatic Agents (DMARD)
9.	ruxolitinib
10.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)

Related Therapies and Procedures

1.	Therapeutics
2.	Renal Dialysis (Hemodialysis)